Member Info for Danielm89

AstraZeneca has extended its drug delivery collaboration with #APTA Aptamer Group. The revised deal sets AstraZeneca up to build on research into the use of aptamer molecules to target renal cells

Update on this work soon

Yes that’s right #APTA already in bed with Zeneca #RNS

Arron tolley:

“We hope the technology will have a huge impact in the diagnostic and therapeutic space. So, we are developing binders and working with external partners for the large scale manufacturing. Any commercial product needs to be manufacturable at high scale. So we are addressing that.”

“Large scale, commercial product, external partners, high scale”

🤔😉

Https://www.linkedin.com/pulse/global-aptamer-market-2024-2030-industry-poised-growth-lwcqf?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

Look at the market size.. and market leaders 😉

List of TOP KEY PLAYERS in Aptamer Market Report are -

• TriLink BioTechnologies

• AptaBharat

• SomaLogic

• AM Biotechnologies

• Aptamer Sciences

• Base Pair Biotechnologies

• Aptamer Group

• Aptagen

• Aptus Biotech

• NeoVentures Biotechnology

• Ray Biotech

• Vivonics

Can’t place below 1p, nominal is 1p

Recon we see a contract before the presentation March 7th

“Did we just revolutionise clinical diagnostic”

Adam Hargreaves:

“Yes; diagnostic and therapeutic options.”

Not an Aptamer (nucleotides) and not an antibody (proteins). It has both binding arms; it has high affinity; and it is rapid. It is called Optimer+, for:

#cancer #geneknockdown #infection #drugconjugates

“Evaluation processes are ongoing within the Company and with external partners to optimise the development and large-scale manufacturing, with an active marketing strategy to follow”

LARGE SCALE 👀

 

Did APTA just revolutionise clinical diagnostics

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "Since we received the proceeds of the September fundraise, the team has worked hard to accelerate the development of Optimer®+ and to show the new platform's capabilities. The development of this platform is integral to our mission to stay at the forefront of binder technologies. Both the lab-based research and the initial animal experiments suggest that Optimer®+ will be well placed to deliver the next generation of binders to enable the targeted delivery of precision medicines. This is an area where we are seeing increasing interest due to the unmet needs across gene therapy and precision chemotherapy."

Https://x.com/theunsophistic2/status/1762117653475233868?s=46&t=4s-AQzZhMmeWz3Ire1AEsA

Https://www.linkedin.com/pulse/aptamers-market-set-surge-forecasted-double-digit-growth-ram-songara-vyayf?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

3% of the company bought this morning

The business counts three-quarters of the world’s top 20 pharmaceutical companies among its clients, including Japan’s largest drugmaker, Takeda. It is working with the UK’s top drugs firm, AstraZeneca, on kidney disease treatments; with Cancer Research UK to develop aptamers as targeted treatments for chronic myelomonocytic leukaemia, a rare type of blood cancer; with South Korea’s PinotBio to develop precision chemotherapy treatments; and with Gene Therapeutics in the US to create gene therapies.

https://aptamergroup.com/aptamer-and-pinotbio-collaborate-to-develop-new-therapeutic-drug-conjugates/

Aptamer Group is working on many important diagnostic and therapeutic targets to support its customers and collaborators, including Cancer Research UK and AstraZeneca to develop targeted drug delivery for kidney disease.

APTA

Today we announce a trading update for H1. 

 

Highlights include:

✅ £1.4M signed deals to date to be progressed through the laboratories

💰 Cash reserves of £2.1M at the end of Jan

🧬 Strong progress in targeted delivery vehicles for gene therapy with a top pharma partner

🔬 Internal success with generation of IHC data and binders trialled by a top 5 pharma partner showing promise

🎯 £1.5M deals at advanced stage negotiations. 

Https://stockhead.com.au/energy/oversubscribed-13m-placement-places-conrad-asia-energy-on-the-fast-track-towards-gas-production/

Nice steady rise to 1p pre news on contracts

Https://bnnbreaking.com/breaking-news/health/pioneering-the-future-aptamer-group-and-neuro-bios-joint-venture-to-combat-alzheimers-with-innovative-detection-tools

Https://www.business-live.co.uk/technology/york-life-sciences-pioneer-aptamer-28682556.amp

Thing is, that was unexpected and on the face of it nothingness news. (But potentially game changing)

Seller took it below 1p

Safe to assume their finished

Held its gains and should build strong from here no pump and dump

Serious volume 37m highest ever 47m

Next few sessions should be interesting, still oversold on the chart